MoonLake Immunotherapeutics

Stories

MoonLake's Nanobody drug clears its second Phase 3 test

Advancing sonelokimab toward its first filings

MoonLake's experimental drug sonelokimab hit its main goal in a second late-stage trial, this time in psoriatic arthritis. The win moves the small Swiss biotech's Nanobody drug closer to two separate markets.

Updated 2 hours ago

MoonLake pushes sonelokimab toward FDA approval for a painful skin disease

New Capabilities

Targeting BLA submission by end-September 2026; proposed $150 million equity offering on June 22 to fund commercialization

Hidradenitis suppurativa causes painful, recurring abscesses in the skin folds of about 1 in 100 people. For most of the past decade, one drug controlled it well enough to win U.S. approval.

Updated Jun 23